Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 2/3 1

Status

Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 2Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Neoplasm Metastasis 8Esophageal Neoplasms 8Carcinoma, Hepatocellular 7Melanoma 6Lung Neoplasms 6Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Pathologic Complete Response 2Nasopharyngeal Carcinoma 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Breast Neoplasms, Male 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms 1Pleural Mesothelial Neoplasm 1

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Melanoma × Immunotherapy × 1 year × Clear all
NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT04594187 2026-02-17

MelPORT

M.D. Anderson Cancer Center

Phase 2 Recruiting
168 enrolled
Dermatologic

Melanoma

NCT07407166 2026-02-17

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Institute of Oncology Ljubljana

Phase NA Recruiting
40 enrolled
Dermatologic

Melanoma

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

University of Oklahoma

Active not recruiting
72 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

NCT06146920 2025-11-18

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Massachusetts General Hospital

Phase NA Active not recruiting
39 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡